Evaluation of efficacy of cyproterone acetate monotherapy in prostatic cancer

The trial conducted in the Primorsk Regional Cancer Hospital of Vladivostok and P. A. Herzen Moscow Research Cancer Institute studied effectiveness and tolerance of cyproteron acetate (CA) monotherapy and maximal androgenic block (MAB) (CA + surgical or CA + drug castration). A total of 70 patients...

Full description

Saved in:
Bibliographic Details
Published inUrologii͡a︡ (Moscow, Russia : 1999) no. 4; p. 25
Main Authors Gurina, L I, Iudin, S V, Rusakov, I G, Bystrov, A A
Format Journal Article
LanguageRussian
Published Russia (Federation) 01.07.2003
Subjects
Aged
Androgen Antagonists - therapeutic use
Antineoplastic Agents - therapeutic use
Combined Modality Therapy
Cyproterone Acetate - therapeutic use
Drug Tolerance
Humans
Male
Middle Aged
Neoplasm Staging
Orchiectomy
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - surgery
Online AccessGet more information

Cover

More Information
Summary:The trial conducted in the Primorsk Regional Cancer Hospital of Vladivostok and P. A. Herzen Moscow Research Cancer Institute studied effectiveness and tolerance of cyproteron acetate (CA) monotherapy and maximal androgenic block (MAB) (CA + surgical or CA + drug castration). A total of 70 patients with localized, locally advanced and generalized prostatic cancer entered the trial. They were divided into three groups: group 1 (54.3%) patients received CA monotherapy--300 mg/day, group 2 (27.1% patients) was exposed to MAB by surgical castration and received CA in a dose 200 mg/day, group 3 (18.6% patients) were exposed to MAB by drug castration and received 200 mg/day CA. The results obtained show that CA monotherapy and MAB have similar effectiveness in favourable prognostic signs. CA monotherapy was less toxic than CA combination with castratio.
ISSN:1728-2985